The protein phosphatase inhibitor-1 (PPI-1) inhibits phosphatase type-1 (PP1) only when phosphorylated by protein kinase A and could play a pivotal role in the phosphorylation/dephosphorylation balance. Rat cardiac PPI-1 was cloned by reverse transcriptase-polymerase chain reaction, expressed in Eschericia coli, evaluated in phosphatase assays, and used to generate an antiserum. An adenovirus was constructed encoding PPI-1 and green fluorescent protein (GFP) under separate cytomegalovirus promotors (AdPPI-1/GFP). A GFP-only virus (AdGFP) served as control. Engineered heart tissue (EHT) from neonatal rat cardiomyocytes and adult rat cardiac myocytes (ARCMs) were used as model systems. PPI-1 expression was determined in human ventricular samples by Northern blots. Compared with AdGFP, AdPPI-1/GFP-infected neonatal rat cardiomyocytes displayed a 73% reduction in PP1 activity. EHTs infected with AdPPI-1/GFP exhibited a fivefold increase in isoprenaline sensitivity. AdPPI-1/GFP-infected ARCMs displayed enhanced cell shortening as well as enhanced phospholamban phosphorylation when stimulated with 1 nM isoprenaline. PPI-1 mRNA levels were reduced by 57±12% in failing hearts with dilated and ischemic cardiomyopathy (n=8 each) compared with nonfailing hearts (n=8). In summary, increased PPI-1 expression enhances myocyte sensitivity to isoprenaline, indicating that PPI-1 acts as an amplifier in β-adrenergic signaling. Decreased PPI-1 in failing human hearts could participate in desensitization of the cAMP pathway.
M
any biological processes are controlled by the phosphorylation state of regulatory proteins. Steady-state phosphorylation reflects the balance between protein kinasemediated phosphorylation and protein phosphatase-mediated dephosphorylation and can be enhanced both by increased kinase activity and by inhibition of phosphatases. The protein phosphatase inhibitor-1 (PPI-1) is an interesting potential modulator of this balance because it acts as a potent and highly specific inhibitor of protein phosphatase type-1 (PP1) only when phosphorylated by the cAMP-dependent protein kinase A (PKA; 1, 2). As such, it could provide amplification (positive feedback) of PKA-mediated signals.
In cardiac muscle, PKA is centrally involved in the β-adrenergic signaling pathway. By phosphorylating sarcolemmal L-type Ca 2+ channels, sarcoplasmic ryanodine receptors and phospholamban (PLB), as well as the myofibrillar proteins troponin I and myosin binding protein C, this pathway provides the most powerful regulation of intracellular Ca 2+ homeostasis and Ca 2+ sensitivity and, thereby, of contractility and relaxation. In the mammalian heart, the phosphatases PP1 and PP2A are predominant (3, 4) , and their pharmacological inhibition in isolated cardiac myocytes resulted in a marked increase in twitch amplitude (4) . This indicates significant activity of both kinases and PP1/PP2A under basal conditions.
Despite its early discovery (5), little is known about the role of PPI-1 in general, and its role in the heart remains obscure. PPI-1 was detected in the heart (6) and in cardiac myocytes (7) . PPI-1 was also shown to be hyperphosphorylated in the presence of isoprenaline (6) (7) (8) , indicating its involvement in the β-adrenergic signaling pathway. However, its protein level appears to be extremely low (6, 7, 9) and/or its immunological detection is difficult. This may explain why early reports concluded its absence in the heart (10) . In addition, at present, no antibody is commercially available; one antibody was retracted from the market due to technical problems (personal communication, Ms. Wedekind, Serotec, Düsseldorf, Germany). In addition, recent studies in mice in which PPI-1 was inactivated by gene targeting did not reveal a clear phenotype, in terms of either learning behavior (11) or smooth muscle contraction and its regulation by β-adrenergic signaling (12) . Both findings were unexpected and surprising.
This study sought to shed some light on the role of PPI-1 in the heart. We chose an adenovirusmediated gene transfer approach in order to achieve sufficient gene transfer efficacy in cardiac myocytes. This enabled us to evaluate the impact of PPI-1 overexpression on a short time scale and devoid of systemic influences. Our experiments are compatible with a positive feedback role of PPI-1 in the β-adrenergic signaling pathway in cardiac myocytes. Given the well-known desensitization of this pathway in human heart failure, it was interesting to evaluate whether expression of PPI-1 was altered in failing human hearts. Indeed, Northern blots demonstrated a >50% down-regulation of cardiac PPI-1 mRNA levels in heart failure of different etiology, which may contribute to β-adrenergic desensitization in human heart failure.
MATERIALS AND METHODS
Cloning, bacterial expression and in vitro phosphorylation of cardiac PPI-1, and generation and affinity purification of polyclonal antibody Cardiac PPI-1 was cloned from rat cardiac poly A + RNA by reverse transcriptse-polymerase chain reaction (RT-PCR) (forward primer: 5'-GCGGCCATGGAGCCCGACAAC-3'; backward primer: 5'-CATCCAGTGTCCATGAACTTCC-3') according to the published sequence of PPI-1 from rat skeletal muscle (13; acc. no. J05592). The PCR product was subcloned into the pBluescript vector (Stratagene, Pasadena, CA) and sequenced with Sequenase (USB, Cleveland, OH). The sequencing result was verified by cycle sequencing of the entire open reading frame in both directions. Recombinant PPI-1 protein was generated by cloning the complete cDNA of rat heart PPI-1 into the pGEX-λT expression vector (Stratagene). The plasmid was transformed into competent Escherichia coli BL21 (Novagen Madison, WI) to express PPI-1/glutathione-Stransferase (PPI-1-GST). PPI-1-GST was purified from clarified bacterial lysate by affinity purification with glutathione agarose beads. Loaded beads were washed three times, and recombinant PPI-1 was released by thrombin cleavage. To raise a polyclonal PPI-1 antibody, we immunized a rabbit with the purified rat PPI-1 (Eurogentec, Brussels). After three rounds of booster immunization (on days 14, 28, and 56), total serum was collected and purified by affinity chromatography on a PPI-1 Sepharose column. The specificity of the antiserum for PPI-1 was tested by comparison to preimmune serum in Western blots. The recombinant PPI-1 protein was phosphorylated by the catalytic subunit of PKA in a total reaction volume of 100 µl . The reaction mixture contained 50 µl of PPI-1 (0.5 mg/ml) in phosphate-buffered saline and 50 µl of the reaction mixture, consisting of 6 mM MgCl 2 , 0.1 mM ATP, and 20 U of the catalytic subunit of PKA. After 60 min at 37°C, the reaction was terminated by placing the mixture in a boiling water bath for 5 min. Phosphorylated PPI-1 was stored at 4°C for less than 3 days.
Isolation of endogenous PPI-1
PPI-1 was isolated and enriched from rat brain (wet weight, 365 mg), rat skeletal muscle (wet weight, 2340 mg), rat heart (wet weight, 383 mg), and human heart (wet weight, 343 mg) tissue as published previously (8) . In brief, the tissue was homogenized in ice-cold 1.5% trichloroacetic acid (TCA [wt/vol], 4 mM EDTA). The homogenate was centrifuged at 20,000g for 30 min, TCA concentration in the supernatant was increased to 19%, allowed to stand at 4°C for 12 h, and was centrifuged at 20,000g for 15 min. The pellet was resuspended in 0.5 M Tris (pH 8.0), boiled for 10 min, and centrifuged as previously described. The supernatant was dialyzed for 16 h against water, centrifuged at 20,000g for 20 min, and diluted 1:1 with 100 mM Tris-HCl (pH 7.4), 2 mM EDTA, and 50 mM β-mercaptoethanol.
Northern and Western blot analysis
Northern blots were prepared from 20 µg total RNA as described previously (14) . A 32 P-labeled 608-bp fragment of human GAPDH cDNA and a 640-bp 32 P rat PPI-1 cDNA were used as specific probes.
Western blots were performed with polyclonal antibodies raised against rat heart PPI-1 (PPI-1 Ab diluted 1/5000), rabbit skeletal muscle PPI-1 (kindly provided by P. Greengard, G 184 diluted 1/200), PLB (phospholamban phosphorylated at Ser16 (PSer16-PLB diluted 1/5000; PhosphoProtein Research, West Yorkshire, UK), glycogen synthase kinase 3β (GSK3β diluted 1/1000; BD Transduction Laboratories, Los Angeles, CA), phospho-GSK3β (diluted 1/1000, Cell Signaling Technology, Beverly, MA) calsequestrin (CSQ diluted 1/2500; Dianova, Hamburg, Germany), and phospho-dopamine and cAMP-regulated neuronal phosphoprotein (DARPP)-32 peptide (diluted 1/1000, Cell Signaling Technology) as described previously (14) .
For blocking experiments, 15 ml of an antibody dilution (see above) was incubated with 80 µg recombinant PPI-1 for 15 min at room temperature with gentle agitation before use.
Construction, propagation, and purification of recombinant adenoviruses
A recombinant adenovirus that carries the cardiac PPI-1 gene (AdPPI-1/GFP) was generated by cloning of the full-length cDNA into the shuttle vector pAdTrack-CMV. Subsequently, this vector was cotransfected with the backbone vector pAdEasy-1 into recombination-competent E. coli (BJ5138) as described previously (15) . In this system, PPI-1 and the green fluorescent protein (GFP) expression are under control of separate CMV promotors. A GFP-only virus (AdGFP) was used as control. Viruses were propagated in HEK 293 cells and purified by cesium chloride density gradient centrifugation. Virus content was determined by measuring DNA concentration after proteinase K digestion, extraction with phenol and chloroform, and ethanol precipitation. DNA (21 µg) was assumed to be 1 pM or 6.23×10 11 virus particles. The titer of biologically active virus (bav) was determined by infecting a known number of neonatal rat cardiac myocytes (NRCMs) with serial dilutions of the GFP-containing viruses. A multiplicity of infection (MOI) of 1 was defined as the amount of virus necessary to positively transfect 100% of cells after 48 h as determined by GFP epifluorescence.
Cardiac myocyte isolation, culture, and infection
NRCMs were isolated from 1-to 3-day-old neonates by serial trypsin/DNase digestion as described previously (16) . NRCMs were plated at a density of 100,000 cells/cm 2 in medium supplemented with 0.1 mM 5'-bromo-2'-deoxyuridine (BrdU; Sigma, St. Louis, MO) to prevent overgrowth by nonmyocytes. NRCMs were infected with AdPPI-1/GFP and AdGFP 72 h after plating and cultured for an additional 48 h in medium (10% fetal calf serum, 0.1 mM BrdU). Adult rat ventricular myocytes (ARCMs) were isolated using a low calcium (LC) solution (in mM: NaCl 120, KCl 5.4, MgSO 4 5, pyruvate 5, glucose 20, taurine 20, HEPES 10, and nitrilotriacetic acid 5, preoxygenated with 100% O 2 ) and collagenase (17) . After they were washed, myocytes were plated in M199 medium with the addition of 0.2% wt/vol bovine serum albumin, 100 mM ascorbate, 5 mM creatine, 5 mM taurine, 2 mM carnitine, 0.1 µM insulin, and Pen/Strep. ARCMs (10 4 rod-shaped myocytes) were infected in 3-cm dishes with AdPPI-1/GFP or AdGFP with a MOI of 10 4 for 24 h.
Phosphatase activity
Phosphatase activity of cell lysates from NRCMs was determined as described previously (6) with 32 P phosphorylase a as substrate. The reaction was started by adding aliquots of homogenates or recombinant PPI-1 and stopped by addition of 50% trichloroacetic acid. Precipitated protein was sedimented by centrifugation, and the radioactivity in the supernatant was determined.
Engineered heart tissue (EHT) and isometric force measurement
Circular EHT was prepared as described previously (18) . EHTs represent a spontaneously forming 3-D heart tissue-like structure that exhibits spontaneous, regular, and coherent beating and allows measurement of force of contraction under isometric conditions in organ baths.
Freshly isolated cardiac cells from neonatal rats were mixed with collagen type I matrigel (Tebu, Frankfurt, Germany) and Dulbecco's modified Eagle's medium containing horse serum and chick embryo extract. The reconstitution mix was pipetted into circular casting molds, and culture was performed as described previously (18) . After 11 days in culture, EHTs were infected with AdPPI-1/GFP or AdGFP control (MOI 50) by adding the respective amount of virus stock to the culture medium, and isometric force of contraction was measured 48 h later in organ baths containing gassed Tyrode's solution. Electrically stimulated EHTs were stretched to the length at which force of contraction was maximal, and inotropic and lusitropic responses to cumulative concentrations of calcium (0.4-2.8 mM) and isoprenaline (0.1-1000 nM) were recorded. Contractile activity was evaluated with a PC-assisted system (BMON2, Ingenieurbüro Jäckel, Hanau, Germany).
Video-edge detection of fractional cell shortening in ARCMs
Contraction experiments in ARCMs were performed as described previously (17) after adenoviral-mediated gene transfer for 24 h. Contraction amplitude and rates of contraction and relaxation were assessed by video-edge detection. Myocyte shortening was calculated as the percent change in myocyte length from resting to minimal myocyte length. After 10 min of baseline stabilization, cell shortening of two to three cells per preparation was recorded as baseline data at 1 mM Ca
2+
. Subsequently, a single concentration of 1 nM isoprenaline was superfused, and data of five to six myocytes were collected when the contractility of the indicator myocyte was stably increased (3-5 min).
Human myocardial tissue
Failing hearts were obtained from patients undergoing orthotopic heart transplantation due to end-stage heart failure (NYHA functional class III-IV) resulting from idiopathic dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM). Myocardial tissue from eight nonfailing (NF) donor hearts that could not be transplanted because of technical reasons was used for comparison. Neither the donor patient histories nor 2-D echocardiography revealed signs of heart disease. All patients or relatives, respectively, gave written informed consent before the operation. The study was reviewed and approved by the Ethical Committee of the University Clinics of Hamburg (Az. 532/ 116/ 9.7.1991). Patient details are shown in Table 1 .
Statistical analysis
Data are presented as mean±SE. Statistical analysis was performed using Student's t test to compare two groups and repeated measures ANOVA to compare concentration-response curves. A value of P<0.05 was considered statistically significant.
RESULTS

Molecular cloning of cardiac PPI-1 cDNA
PPI-1 was cloned from rat heart by RT-PCR. As shown in Figure 1A , the cDNA sequence of the new cardiac clone (570 bp) encoding the entire reading frame of 171 amino acids differed from the published cDNA sequence for rat skeletal muscle PPI-1 (13; acc. no. J05592). The single nucleotide exchange (adenine instead of guanine) results in an amino acid exchange at position 27 (lysine instead of glutamine) near the regulative threonine-35 phosphorylation site. This region appears to be highly conserved in all species studied and similarly present in the related DARPP-32 (Fig. 1A) .
Biological activity of recombinant rat heart PPI-1
The recombinant rat heart PPI-1 was expressed in E. coli as a GST fusion protein, purified, digested, and phosphorylated in vitro by the catalytic subunit of PKA. Its biological activity was tested in a phosphatase assay, using 32 P-labeled phosphorylase a as substrate and homogenates from NRCMs as a source for phosphatase activity. As shown in Figure 1B , PPI-1 inhibited cardiac phosphatases with high potency (75 nM) in its PKA-phosphorylated form and with ~19-fold lower potency (1402 nM) in its unphosphorylated form. Successful phosphorylation of recombinant PPI-1 by PKA was confirmed by Western blotting with a DARPP-32 antibody (inset in Fig. 1B ). This antibody is a phosphorylation-selective monoclonal antibody raised against a phosphopeptide encompassing the DARPP-32 cAMP-dependent phosphorylation site (19) . Given the almost identical sequence of DARPP-32 and PPI-1 in that region (see Fig. 1A ), the antibody also recognizes the phosphorylated form of PPI-1 (19) .
Efficiency of gene transfer and impact on phosphatase activity
By the concomitant expression of GFP in the bicistronic adenovirus vectors, the efficiency of gene transfer in cardiac myocytes was evaluated in living monolayer cultures (2-D) and EHT (3-D) by epifluorescence and confocal microscopy 24-48 h after infection. In EHT, the number of cells transfected with AdPPI-1/GFP increased with increasing virus titers (multiplicity of infection [MOI]; Fig. 2A ). In parallel, average PPI-1 protein levels increased MOI-dependently (Fig. 2B) . Infection of ARCMs for 24 h resulted in transfection efficiencies of typically >90% at a MOI of 10 4 . Under this condition, average PPI-1 protein levels were significantly increased (Fig. 6B) . Note that transfection efficiency depended on the culture format. To reach a transfection efficiency of >90%, MOI of 1, 50, and 10,000 were needed in 2-D cultures of NRCMs, EHTs, and ARCMs, respectively.
To test the biological activity of AdPPI-1/GFP-expressed PPI-1, phosphatase activity was measured in homogenates of monolayer cultures of NRCMs that had been infected either with AdPPI-1/GFP or AdGFP (MOI 10) and stimulated with 100 nM isoprenaline for 5 min. As shown in Figure 3 , PP activity was reduced by 73% in PPI-1 overexpressing cardiac myocytes (AdPPI-1/GFP: 0.55±0.14; AdGFP: 1.79±0.13 pmol/µg protein/min; P<0.01, n=4).
Overexpression of PPI-1 sensitizes EHTs to isoprenaline
EHTs were infected with AdPPI-1/GFP or with AdGFP on day 11 (MOI 50), cultured for an additional 48 h, and then assayed for basal force of contraction as well as inotropic responses to calcium and isoprenaline (Fig. 4) . In both AdPPI-1/GFP-and AdGFP-infected EHTs, calcium and isoprenaline in the presence of low calcium evoked a typical increase in isometric force. In AdPPI-1/GFP-infected EHTs, both concentration-response curves were significantly upwardly shifted (Fig. 4A) . Moreover, as demonstrated in Figure 4B , the EC 50 for the effect of isoprenaline, but not that of calcium, was shifted leftward from 5.6±3.0 nM in control-infected EHTs to 1.0±0.2 nM, indicating increased isoprenaline sensitivity. In parallel, relaxation time was significantly shortened in AdPPI-1/GFP-infected EHTs (Fig. 5) , most notably under basal conditions.
Overexpression of PPI-1 increases contractile response to isoprenaline in ARCMs
Single-cell shortening of AdPPI-1/GFP-and AdGFP-infected myocytes was measured 24 h after adenoviral infection (MOI 10 4 ) under superfusion with Krebs-Henseleit buffer and electrical field stimulation of 0.5 Hz. AdPPI-1/GFP-and AdGFP-infected ARCMs did not differ in basal cell shortening (5.0±0.7% vs. 4.2±0.6%; Fig. 6A ). In contrast, upon stimulation with 1 nM isoprenaline, cell shortening rate was 37% higher in AdPPI-1/GFP-infected than in AdGFPinfected ARCMs (10.9±0.4% vs. 8.0±0.5%; Fig. 6A ).
Overexpression of PPI-1 increases isoprenaline-stimulated PLB phosphorylation in ARCMs
To test whether increased cell shortening was associated with increased phosphorylation of PLB, we homogenized cells after measurement of cell shortening and subjected them to Western blotting with a Ser16-PLB phospho-specific antiserum and antiserum against PPI-1 and internal control CSQ (Fig. 6B) . In ARCMs perfused for 5 min with buffer, no PLB phosphorylation was detectable. In contrast, cells perfused with 1 nM isoprenaline showed a phospho-specific signal that was clearly stronger in AdPPI-1/GFP-infected than in AdGFP-infected ARCMs. AdPPI-1/GFP-infected ARCMs showed the expected overexpression of PPI-1, whereas control cells showed either no or only a faint band of the respective size. PPI-1 overexpression did not affect the phosphorylation level of glycogen synthase kinase 3β, measured also by Western blotting, either under basal or under isoprenaline-stimulated condition. In the latter, phosphorylation was increased as expected (20, data not shown).
PPI-1 expression is decreased in human heart failure
PPI-1 mRNA levels were analyzed in left ventricle myocardial samples by Northern blotting and were found to be reduced by a mean of 57% in failing hearts with dilated or ischemic cardiomyopathy as compared with donor hearts (heart failure: 0.81±0.1 arbitrary density units, n=16, vs nonfailing controls: 1.87±0.28 arbitrary density units, n=8; Fig. 7 ). The decrease appeared regardless of the underlying etiology.
Immunodetection of PPI-1 protein in human heart
Immunoblots of homogenates from human left ventricle myocardial tissue (30 µg per lane) were probed with the PPI-1 antiserum against rat heart PPI-1 as well with the G 184 antibody against rabbit skeletal muscle PPI-1 and demonstrated a prominent band at ∼29 kDa that closely comigrated with the strong signal in AdPPI-1-infected NRCMs (Fig. 8A) . The same signal was seen in NRCM and rat cardiac tissue (data not shown). However, comigration was not perfect, and the band was also observed in immunoblots probed with the preimmune serum (data not shown). In addition, the band in native tissues/cells was not blocked by preincubation of the antiserum with recombinant PPI-1 (data not shown), whereas the strong signal in AdPPI-1-infected NRCMs was. To increase the sensitivity/specificity of our antiserum and to test whether it recognizes native PPI-1, we affinity-purified the antiserum with recombinant rat heart PPI-1.
Trichloroacetic acid extracts from large amounts of various tissues (>0.3 g) were evaluated with the purified antiserum, with G 184 and with preimmune serum (Fig. 8B) . Both the purified antiserum and G 184, but not the preimmune serum, detected a specific band of the correct size in rat brain and rat skeletal muscle. A faint band was detected in rat heart, but not in human heart. Taken together, these experiments demonstrate that the immunosignal in standard homogenates of rat or human heart does not represent PPI-1 (but an unrelated nonspecific band) and that endogenous concentrations of PPI-1 are below the detection limit of standard Western blots, at least under our experimental conditions. DISCUSSION PPI-1 has been demonstrated to be a potent and highly specific inhibitor of PP1 that is active only after phosphorylation by PKA (1, 2, 21, 22 ). This mechanism makes it a potentially interesting element of the β-adrenergic signaling cascade, which provides the most powerful stimulatory regulation of cardiac contractility and relaxation. Indeed, isoprenaline increased PPI-1 phosphorylation and led to the inhibition of PP1 activity in guinea pig myocardium (6) (7) (8) . However, the role of PPI-1 in the heart remains largely unknown.
Here, PPI-1 was cloned for the first time from the heart. Unexpectedly, the cDNA sequence differed from the published cDNA sequence for rat skeletal muscle PPI-1 (13) by a single nucleotide exchange (adenine instead of guanine), resulting in an amino acid exchange at position 27 (lysine instead of glutamine). This position is close to the regulatory threonine-35 phosphorylation site in a region that is highly conserved throughout various species (human, rat, rabbit). It is also found in the related DARPP-32 (23) . The consequence of the amino acid exchange from an acidic to a basic residue is unknown at present but could represent a hitherto unknown single nucleotide polymorphism. Phosphatase assays confirmed that the recombinant rat heart PPI-1 functions as a potent inhibitor of cardiac phosphatases in its PKA-phosphorylated form.
When isolated cardiac myocytes were challenged with calyculin A, a potent inhibitor of PP1 and PP2A, twitch amplitude doubled and further stimulation by isoprenaline was without effect (4, 24) . Under the same condition, the nonspecific protein kinase inhibitor staurosporine markedly decreased force of contraction and subsequent addition of calyculin A had no effect. These experiments demonstrate that both protein kinases and phosphatases are active in cardiac myocytes under basal, unstimulated conditions. However, they do not answer the question of whether PPI-1 plays a specific role under these or other conditions. In the present study, we investigated the impact of enhanced PPI-1 expression on contractile properties in two in vitro model systems, EHTs and ARCMs, through adenoviral gene transfer. The principal feasibility of the adenovirus approach was tested in NRCMs that were stimulated with isoprenaline for 5 min to enhance the phosphorylation of PPI-1. As expected, homogenates from cells infected with AdPPI-1/GFP exhibited a 73% reduction in phosphatase activity as compared with controls. The EHT model system was chosen for several reasons: EHTs represent 3-D heart-tissue-like cardiac myocyte cultures that allow determination of standard parameters of contractile function such as twitch tension, resting tension, and relaxation time under isometric conditions. They provide cells with a relatively physiological 3-D environment, and they are easy to transfect with adenovirus with high efficiency (16) . On the other hand, EHTs do not represent a pure cardiac myocyte population but rather a mixture of various cell species derived from immature cardiac myocytes (18) . That may obscure some of the cardiac myocyte-specific effects. Consequently, purified ARCMs were chosen as an additional model.
EHTs that had been infected with PPI-1-encoding virus showed significantly higher contractile force and cell shortening, respectively, than those infected with control virus. The fact that PPI-1-overexpressing EHTs demonstrated significant increases in force of contraction throughout the Ca 2+ and isoprenaline concentration-response curve and hastened relaxation mostly under unstimulated conditions was somewhat unexpected, because PPI-1 needs to be phosphorylated for its activity. However, as previously outlined, there appears to be significant basal activity of protein kinases in cardiac myocytes, and this could explain the difference in basal contractility and relaxation. Indeed, experiments with a phospho-specific DARPP-32 antibody that recognizes phosphorylated, but not unphosphorylated, PPI-1 (19) , demonstrated that the overexpressed PPI-1 in NRCMs is partly phosphorylated under unstimulated conditions (data not shown). In addition, differences in basal contractility are difficult to interpret in the EHT model because it is affected by many factors such as the degree of tissue formation in EHTs and the length-force relation.
Importantly and in accordance with the prevailing hypothesis of the place of PPI-1 in β-adrenergic signaling, experiments in EHTs revealed a PPI-1-associated fivefold sensitization to the positive inotropic effect of isoprenaline. Similarly, cell shortening of ARCMs at an EC 50 concentration of isoprenaline was significantly enhanced. Under this condition, PLB phosphorylation was enhanced when compared with control-infected ARCMs. In the present study, PLB phosphorylation was used as a sensitive marker for other PKA target proteins (such as L-type calcium channels, troponin I, C-protein, or the ryanodine receptor) for three reasons. First, it is easy to determine. Second, phosphorylation of PLB increases in parallel with troponin I and C-protein when human cardiac samples are challenged with isoprenaline (25) . Third, it is accepted that PLB plays a prominent role in the regulation of cardiac contractility in response to β-adrenergic stimulation (26) . Our present finding of a concomitant enhancement of PLB phosphorylation and cell shortening provides a plausible link between overexpressed PPI-1, enhanced inhibition of phosphatases, less dephosphorylation of PLB, disinhibition of SERCA, and improved diastolic and systolic contractile function. Accordingly, phosphorylation of PLB was undetectable in both PPI-1-overexpressing and control-infected ARCMs in the absence of isoprenaline, and cell shortening was similar, strengthening the idea that regulation of the phosphorylation level of PLB by PPI-1 is central to the observed effects of PPI-1 overexpression. Alternatively, the effects of PPI-1 overexpression could be due to or could be obscured by regulation of energy metabolism enzymes such as glycogen synthase or glycogen phosphorylase, well-known targets of PP1 in liver (27) (28) (29) . However, our Western blot data did not provide evidence for such an effect. Collectively, our data support the idea that PPI-1 acts as an amplifier in the β-adrenergic signaling pathway and that an increase in its level sensitizes cardiac myocytes to β-adrenergic agonists.
Given that one of the hallmarks of human heart failure is desensitization of the β-adrenergic signaling pathway (30) , it was tempting to analyze expression levels of PPI-1 in failing human hearts. Here, we report for the first time that PPI-1 transcript levels are decreased in both dilated and ischemic cardiomyopathy. The degree of this reduction is marked (-57%) when compared with other known alterations in gene expression, and its order of magnitude is comparable to the level of down-regulation of β 1 -adrenergic receptors (31) . This finding is of particular interest because phosphatase activity was found to be increased 2.5-fold in human heart failure (9). Because PP1 is potently inhibited by its specific regulator PPI-1, the markedly decreased PPI-1 expression observed in our study could at least partially explain the findings of Neumann et al. (9) . Through this mechanism, the decrease in PPI-1 could contribute to the reduced phosphorylation level of PLB that has been observed under basal (32, 33) and/or isoprenalinestimulated conditions (25) . Similarly, Zakhary et al. (34) described a decrease in basal phosphorylation of troponin I, another well-described target protein of PKA. Thus, we believe that the reduction in PPI-1 could contribute to the reduced inotropic response to β-adrenergic signaling pathway in human heart failure.
In apparent contrast to this hypothesis, Marx et al. provided evidence for hyperphosphorylation of ryanodine receptors in human heart failure and for a decreased amount of phosphatase 1 physically associated with the ryanodine receptor (35) . These researchers explained the apparent contrast between this finding and β-adrenergic desensitization and increased global PP1 activity by the existence of two compartments, a junctional sarcoplasmic reticulum (ryanodine receptor) and a free sarcoplasmic reticulum (PLB). PPI-1 as a cytoplasmatic protein is likely to regulate predominantly the free sarcoplasmic reticulum and thereby may contribute to functional compartmentalization. It is of particular interest that PPI-1 is dephosphorylated and inactivated by protein phosphatase type 2B or calcineurin (36) . PPI-1 could therefore represent a link between cAMP and calcium-dependent signaling pathways in the heart.
Limitations of this study
The present study failed to determine PPI-1 protein levels in human hearts. Whereas Western blots showed a band that migrated with the expected molecular weight of PPI-1, several lines of evidence suggest that this signal does not represent PPI-1: It was similarly seen with the preimmune serum, it did not exactly comigrate with recombinant PPI-1 and it was, in contrast to the strong signal of recombinant PPI-1, not blocked by recombinant PPI-1. The possibility that our antiserum does not recognize rat PPI-1 was excluded by strong and specific signals in TCA extracts from tissues known to contain larger amounts of PPI-1 such as brain and skeletal muscle. These data suggest that endogenous PPI-1 levels in the heart are below the detection limit of standard Western blots. The lack of signal in TCA extracts from human heart may suggest that the antiserum does not recognize human PPI-1 at all and/or that PPI-1 levels are even lower in human than in rat heart. Our difficulties are in line with published data showing that one whole guinea pig heart was necessary for the detection of PPI-1 by Western blots (7, 9) . It remains unclear at present, whether the faint band sometimes seen in uninfected EHTs (Fig.  2B ) and uninfected ARCMs really represents endogenous PPI-1 or a cross-reacting protein. In either case, we believe that the reduction in PPI-1 mRNA levels is so marked that a concomitant reduction in protein levels is likely.
During the review process of this article, a study was published that demonstrates that targeted ablation of PPI-1 in mice resulted in a 23% increase in PP1 activity together with an ∼20% reduction in β-adrenergic contractile response in a working heart preparation (37). This paper suggests that endogenous PPI-1 protein levels (measured by Western blot in homogenates) are unchanged in human heart failure but that PPI-1 phosphorylation is significantly reduced. Moreover, overexpression of a constitutively active PPI-1 mutant restored β-adrenergic responses in myocytes from failing human hearts. Whereas the PPI-1 protein data are somewhat different to our findings, the other data are in very neat accordance to ours and strengthen the view that PPI-1 plays a hitherto unknown modulatory role in the β-adrenergic regulation of cardiac contractility. predicted by the rat heart PPI-1 cDNA was aligned with the primary sequence of rat skeletal muscle (13) , rabbit skeletal muscle (2), human brain PPI-1 cDNA (38) , and bovine DARPP-32 cDNA (23). B) Inhibition of protein phosphatase activity by PPI-1 and protein kinase A phosphorylated PPI-1 (PPI-1-P). The protein phosphatase activity was assayed in homogenates of neonatal rat cardiac myocytes, using phosphorylase a as a substrate in the presence of increasing concentrations of PPI-1 (IC 50 1402 nM) and PPI-1-P (IC 50 75 nM). The specific protein phosphatase activity was quantified in picomoles of 32 Phosphatase activity was measured in cytosolic preparations of NRCM monolayers infected either with AdPPI-1/GFP or AdGFP (control) after stimulation with isoprenaline (100 nM, 5 min). Protein phosphatase activity was reduced by 73% in PPI-1 overexpressing cardiac myocytes (multiplicity of infection, 10; n=4; *P<0.01). response to calcium and isoprenaline was measured in EHTs infected with either AdPPI-1/GFP (n=14) or AdGFP control virus (multiplicity of infection (MOI), 50; n=14; *P<0.05). B) Change in isometric force of contraction normalized to the maximal effect obtained. The response to calcium was not significantly different between both groups. In contrast, the concentration response curve to isoprenaline was significantly shifted to the left in PPI-1 overexpressing EHTs (n=14) compared with AdGFP controls (MOI, 50; n=14; *P<0.05). were probed with the PPI-1 antiserum against rat heart PPI-1 as well with the G 184 antibody against rabbit skeletal muscle PPI-1 and demonstrated a prominent band at ∼29 kDa that closely comigrated with the strong signal in AdPPI-1-infected rat neonatal cardiac myocytes. B) Immunoblot analysis of trichloracetic acid extracts enriched in PPI-1 isolated from rat brain (RB), rat skeletal muscle (RSM), rat heart (RH), and human heart (HH). PPI-1-enriched fractions were probed with the purified PPI-1 antibody or preimmune serum. A protein band of ∼29 kDa (PPI-1) was detected only in PPI-1-enriched extracts isolated from rat brain (1 µg, according to 18 mg tissue), rat skeletal muscle (3 µg, according to 117 mg tissue), and rat heart (1 µg, according to 19 mg tissue; faint band) by the PPI-1 antibody but not the preimmune serum.
